• QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively
• QIAGEN started cross-checking variants in May 2020 and continues to conduct biweekly assessments
• QIAseq SARS-CoV-2 Primer Panel helps with sequencing RNA and identifying mutations

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections ? and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established testing methods. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2. Surveillance of genetic variations will continue on a biweekly basis. ?We are pleased to report the known viral variants have had no impact on the effectiveness of our three SARS-CoV-2 PCR tests ??PCR remains the gold standard for detecting RNA viruses like SARS-CoV-2,? said?Davide Manissero, M.D., Chief Medical Officer - Infection and Immune Diagnostics at QIAGEN.??Further genomic sequencing of SARS-CoV-2 samples worldwide will vastly increase transparency and help us identify and respond to potentially dangerous mutations of the virus,?while at the same time broadening the database we can use to verify if vaccines and tests?continue to be effective.? Variants?with potentially increased transmissibility include VUI 202012/01 (first detected in the United Kingdom), 501Y.V2 (identified in South Africa), and?B.1.1.28 P1?(most recently discovered in Brazil).?As a virus encoded by RNA nucleotides, SARS-CoV-2?frequently mutates due to erroneous or ineffective replication of the virus genome. These mutations can sometimes produce viruses with altered properties or even entirely new strains. To better identify potentially dangerous variants, countries like Germany and the U.S. are increasing the frequency of sequencing positive SARS-CoV-2 samples to monitor the occurrence of potential mutations. In August 2020, QIAGEN launched the QIAseq SARS-CoV-2 solution for comprehensive monitoring of sequence drift of the virus around the world. Consisting of a CoV-2 targeting panel,? the QIAseq Fx UNGS library kit, and QDI bioinformatic analysis solution, this system allows for the identification of both known and novel variants in the CoV-2 genome. A recent paper published by scientists from the Center of Genomics at the School of Medicine at the Loma Linda University in California measured performance variation across several SARS-CoV-2 whole genome sequencing technologies using clinical nasopharyngeal swab samples. Results demonstrated the QIAseq SARS-CoV-2 Primer Panel enabled preferential amplification of the SARS-CoV-2 genome by up to 100-fold compared to human or bacterial genomes in human samples. In comparison with RNA-seq metagenomics-based technologies, it achieved more than 100-fold higher coverage of the SARS-CoV-2 genome, depending on viral load and sequencing depth. Additional Information regarding QIAGEN?s efforts against SARS-CoV-2 can be found?here. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at?http://www.qiagen.com. Forward-Looking Statement   Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading ?Risk Factors? contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.